mHealth Futures is proud to be leading on exploitation and commercialisation of the EmERGE project developing mHealth solutions for the management of stable HIV. We are a member of a consortia of 12 organisations across Europe with clinical sites in Antwerp, Barcelona, Brighton, Lisbon and Zagreb.
EmERGE (Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and Innovation to Generate Evidence for personalised care) is a project funded by the European Union’s Horizon 2020 Researcher and Innovation Programme under Grant agreement no: 643736.
We are developing a mHealth platform under the Acesso Brand to enable self-management of HIV in patients with stable disease. The platform builds upon and integrates the existing mHealth solutions operated by pioneering healthcare providers in the UK and Spain and applies a rigorous co-design approach to ensure patient and clinician input to the solution.
The platform provides users with web based and mobile device applications which interface securely with relevant medical data and facilitates remote access to key healthcare providers. EATG, the European HIV patient organisation, provides a direct and deep interaction with representative patients and clinicians from 5 EU countries.
The platform and interfaces will be validated in a large study of 3900 patients using a tailored HTA process, MAST, specifically developed for the assessment of mHealth solutions including translatability as a key factor.
Acesso for patients at risk of myeloma
mHealth Futures is working with with clinicians at Kings Health Partners (Kings College Hospital NHS Foundation Trust and Guys and St Thomas NHS Foundation Trust) and Sheffield Teaching Hospitals NHS Trust to develop mHealth platform to support management of the chronic condition known as Monoclonal Gammopathy of Undetermined Significance (MGUS)
MGUS is an increasingly common condition (present in 3% of people over 50 years old), diagnosed by the presence an abnormal protein in the blood. Whilst MGUS itself is benign, the risk of progression to active myeloma (blood cancer) is between 1-5% per year. MGUS therefore requires lifelong monitoring but the current system following 6-monthly blood tests has proven difficult to operate, with patients sometimes being overlooked only to develop acute myeloma at a later date. With limited resources to manage this increasing workload in the NHS, there is a well-recognised need for a new approach.
mHealth Futures in partnership with Podmedics are building on technology developed in the EmERGE project to enable patients to self-manage their disease using a mobile phone application securely linked to the hospital database where patients can see the result of a blood test, be assured there is no disease progression, or can be called for a consultation.